Publications

1. Tevaarwerk AJ, Karam D, Gatten CA, Harlos ES, Maurer MJ, Giridhar KV, Haddad TC, Alberts SR, Holton SJ, Stockham A, Leventakos K, Hubbard JM, Mansfield AS, Halfdanarson TR, Chen R, Jochum JA, Schwecke AS, Eiring RA, Carroll JL, Riaz IB, McWilliams RR, Galanis E, Mandrekar SJ. Transforming the oncology data paradigm by creating, capturing, and retrieving structured cancer data at the point of care: A Mayo Clinic pilot. Cancer. 2024 Apr 25 [Epub ahead of print]
   View PubMed
2. Desai A, Smith CJ, Pritchett JC, Leventakos K, West HJ. Examining crossover and postprotocol therapies in first-line immunotherapy trials in non-small cell lung cancer (NSCLC). Cancer. 2024 Feb 14 [Epub ahead of print]
   View PubMed
3. Rivera-Concepcion J, Lo YC, Uprety D, Adjei AA, Ernani V, Leventakos K. A challenging case of stage IV EGFR-mutant lung cancer with histologic transformation and multiple resistance mechanisms. Current Problems in Cancer: Case Reports. 2024; 13:100284
   
4. Williams C, Meyer L, Kawam O, Leventakos K, DeMartino ES. The Faces of Financial Toxicity: A Qualitative Interview Study of Financial Toxicity in Advanced Cancer Patients in Phase I Oncology Trials. Mayo Clin Proc Innov Qual Outcomes. 2023 Dec; 7 (6):524-533 Epub 2023 Nov 15
   View PubMed
5. Desai A, Smith CJ, Ashara Y, Orme JJ, Zanwar S, Potter A, Hocum C, Moffett JN, Schwecke AJ, Manochakian R, Lou Y, Zhao Y, Ernani V, Savvides P, Molina J, Dimou A, Mansfield AS, Parikh K, Leventakos K. Real-World Outcomes With Lurbinectedin in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung Cancer. Clin Lung Cancer. 2023 Dec; 24 (8):689-695.e1 Epub 2023 Sept 17
   View PubMed
6. Agarwal M, Liu A, Almquist D, Langlais BT, Leventakos K, Yu NY, Manochakian R, Ernani V. Chemoimmunotherapy in patients with extensive-stage small cell lung cancer and a poor performance status. Cancer. 2023 Nov 15; 129 (22):3546-3553 Epub 2023 Aug 07
   View PubMed
7. Engstrom LD, Aranda R, Waters L, Moya K, Bowcut V, Vegar L, Trinh D, Hebbert A, Smith CR, Kulyk S, Lawson JD, He L, Hover LD, Fernandez-Banet J, Hallin J, Vanderpool D, Briere DM, Blaj A, Marx MA, Rodon J, Offin M, Arbour KC, Johnson ML, Kwiatkowski DJ, Janne PA, Haddox CL, Papadopoulos KP, Henry JT, Leventakos K, Christensen JG, Shazer R, Olson P. MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer. Cancer Discov. 2023 Nov 1; 13 (11):2412-2431
   View PubMed
8. Agarwal M, Liu A, Langlais BT, Leventakos K, Yu NY, Almquist D, Manochakian R, Ernani V. Chemoimmunotherapy as the First-Line Treatment for Patients With Extensive-Stage Small-Cell Lung Cancer and an ECOG Performance Status 2 or 3. Clin Lung Cancer. 2023 Nov; 24 (7):591-597 Epub 2023 May 26
   View PubMed
9. Webb MJ, Breen WG, Laack NN, Leventakos K, Campian JL, Sener U. Proton craniospinal irradiation with bevacizumab and pembrolizumab for leptomeningeal disease: a case report. CNS Oncol. 2023 Sep 1; 12 (3):CNS101 Epub 2023 July 25
   View PubMed
10. Lo YC, Rivera-Concepcion J, Vasmatzis G, Aubry MC, Leventakos K. Subtype of SCLC Is an Intrinsic and Persistent Feature Through Systemic Treatment. JTO Clin Res Rep. 2023 Sep; 4 (9):100561 Epub 2023 Aug 16
    View PubMed
11. Paweletz CP, Heavey GA, Kuang Y, Durlacher E, Kheoh T, Chao RC, Spira AI, Leventakos K, Johnson ML, Ou SI, Riely GJ, Anderes K, Yang W, Christensen JG, Janne PA. Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non-Small Cell Lung Cancer Patients. Clin Cancer Res. 2023 Aug 15; 29 (16):3074-3080
    View PubMed
12. Shickh S, Leventakos K, Lewis MA, Bombard Y, Montori VM. Shared Decision Making in the Care of Patients With Cancer. Am Soc Clin Oncol Educ Book. 2023 Jun; 43:e389516
    View PubMed
13. Gile JJ, McGarrah PW, Leventakos K, Sonbol MB, Starr JS, Eiring RA, Hobday TJ, Halfdanarson TR. Efficacy of first-line checkpoint inhibitors in combination with chemotherapy in high-grade extrapulmonary metastatic neuroendocrine carcinomas. J Neuroendocrinol. 2023 May; 35 (5):e13283 Epub 2023 May 25
    View PubMed
14. Zhang J, Leventakos K, Leal TA, Pennell NA, Barve M, Paulson S, Bazhenova L, Johnson ML, Chao RC, Velastegui K, Qian C, Spira A. Additional practice-informing adverse event patterns and management in the krystal-1 phase 2 study of adagrasib (MRTX849) in patients with krasg12c-mutated non--small cell lung cancer. Journal of Oncology Navigation & Survivorship. 2023; 14 (11):350
    
15. Desai A, Rakshit S, Bansal R, Ashara Y, Potter A, Manochakian R, Lou Y, Zhao Y, Ernani V, Savvides P, Schwecke A, Moffett N, Hocum C, Leventakos K, Adjei A, Marks R, Molina J, Mansfield AS, Chen ZM, Dimou A. Time from immune checkpoint inhibitor to sotorasib use correlates with risk of hepatotoxicity in non-small cell lung cancer: A brief report. Cancer Treat Res Commun. 2023; 36:100743. Epub 2023 Jul 13.
    View PubMed
16. Luo YH, Liu H, Wampfler JA, Tazelaar HD, Li Y, Peikert T, Liu D, Leventakos K, Chen YM, Yang Y, Chiou SH, Yang P. Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation. J Cancer Res Clin Oncol. 2022 Aug; 148 (8):2099-2114 Epub 2021 Aug 26
    View PubMed
17. Gao RW, Day CN, Yu NY, Bush A, Amundson AC, Prodduturvar P, Majeed U, Butts E, Oliver T, Schwecke AJ, Moffett JN, Routman DM, Breen WG, Potter AL, Rivera-Concepcion J, Hoppe BS, Schild SE, Sio TT, Lou Y, Ernani V, Ko S, Olivier KR, Merrell KW, Garces YI, Manochakian R, Harmsen WS, Leventakos K, Owen D. Dosimetric predictors of pneumonitis in locally advanced non-small cell lung cancer patients treated with chemoradiation followed by durvalumab. Lung Cancer. 2022 Aug; 170:58-64 Epub 2022 June 13
    View PubMed
18. Janne PA, Riely GJ, Gadgeel SM, Heist RS, Ou SI, Pacheco JM, Johnson ML, Sabari JK, Leventakos K, Yau E, Bazhenova L, Negrao MV, Pennell NA, Zhang J, Anderes K, Der-Torossian H, Kheoh T, Velastegui K, Yan X, Christensen JG, Chao RC, Spira AI. Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRAS(G12C) Mutation. N Engl J Med. 2022 Jul 14; 387 (2):120-131 Epub 2022 June 03
    View PubMed
19. Williams C, Chesak S, Pachman DR, Rhee L, Dierkhising R, Leventakos K. Feasibility of virtual stress management and resiliency training (smart) for oncology fellows during the covid-19 pandemic. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2022; 40(16 Suppl):11016.
    
20. Desai A, Scheckel C, Jensen CJ, Orme J, Williams C, Shah N, Leventakos K, Adjei AA. Trends in Prices of Drugs Used to Treat Metastatic Non-Small Cell Lung Cancer in the US From 2015 to 2020. JAMA Netw Open. 2022 Jan 4; 5 (1):e2144923 Epub 2022 Jan 04
    View PubMed
21. Yang F, Wang Y, Tang L, Mansfield AS, Adjei AA, Leventakos K, Duma N, Wei J, Wang L, Liu B, Molina JR. Efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis. Front Oncol. 2022; 12:955440 Epub 2022 Aug 16
    View PubMed
22. Pritchett JC, Borah BJ, Desai AP, Xie Z, Saliba AN, Leventakos K, Coffey JD, Pearson KK, Speicher LL, Orenstein R, Virk A, Ganesh R, Paludo J, Halfdanarson TR, Haddad TC. Association of a Remote Patient Monitoring (RPM) Program With Reduced Hospitalizations in Cancer Patients With COVID-19. JCO Oncol Pract. 2021 Sep; 17 (9):e1293-e1302 Epub 2021 June 04
    View PubMed
23. Xie Z, Saliba AN, Abeykoon J, Majeed U, Almquist DR, Wiedmeier-Nutor JE, Bezerra E, Andrade-Gonzalez X, Hickman A, Sorenson K, Rakshit S, Wee C, Tella SH, Kommalapati A, Abdallah N, Pritchett J, De Andrade M, Uprety D, Badley A, Manochakian R, Ailawadhi S, Bryce AH, Hubbard JM, Gangat N, Thompson CA, Witzig TE, McWilliams RR, Leventakos K, Halfdanarson TR. Outcomes of COVID-19 in Patients With Cancer: A Closer Look at Pre-Emptive Routine Screening Strategies. JCO Oncol Pract. 2021 Sep; 17 (9):e1382-e1393 Epub 2021 June 14
    View PubMed
24. Cathcart-Rake E, O'Connor J, Ridgeway JL, Breitkopf CR, Kaur JS, Mitchell J, Leventakos K, Jatoi A. Patients' Perspectives and Advice on How to Discuss Sexual Orientation, Gender Identity, and Sexual Health in Oncology Clinics. Am J Hosp Palliat Care. 2020 Dec; 37 (12):1053-1061 Epub 2020 Mar 26
    View PubMed
25. Uprety D, Parikh K, Sawkar A, Dimou A, Leventakos K. Changing paradigm in advanced and metastatic non-small cell lung cancer. J Thorac Dis. 2020 Nov; 12 (11):6992-7001
    View PubMed
26. Breen WG, Leventakos K, Dong H, Merrell KW. Radiation and immunotherapy: emerging mechanisms of synergy. J Thorac Dis. 2020 Nov; 12 (11):7011-7023
    View PubMed
27. Uprety D, Halfdanarson TR, Molina JR, Leventakos K. Pulmonary Neuroendocrine Tumors: Adjuvant and Systemic Treatments. Curr Treat Options Oncol. 2020 Aug 29; 21 (11):86
    View PubMed
28. Cathcart-Rake E, O'Connor JM, Ridgeway JL, Breitkopf CR, Guire LJM, Olson EA, Kaur JS, Leventakos K, Jatoi A. Querying Patients With Cancer About Sexual Health and Sexual and Gender Minority Status: A Qualitative Study of Health-Care Providers. Am J Hosp Palliat Care. 2020 Jun; 37 (6):418-423 Epub 2019 Oct 10
    View PubMed
29. McGarrah PW, Leventakos K, Hobday TJ, Molina JR, Finnes HD, Westin GF, Halfdanarson TR. Efficacy of Second-Line Chemotherapy in Extrapulmonary Neuroendocrine Carcinoma. Pancreas. 2020 Apr; 49 (4):529-533
    View PubMed
30. Manohar S, Ghamrawi R, Chengappa M, Goksu BNB, Kottschade L, Finnes H, Dronca R, Leventakos K, Herrmann J, Herrmann SM. Acute Interstitial Nephritis and Checkpoint Inhibitor Therapy: Single Center Experience of Management and Drug Rechallenge. Kidney360. 2020 Jan 30; 1 (1):16-24 Epub 2020 Jan 07
    View PubMed
31. Albitar HAH, Duma N, Leventakos K, Gallo De Moraes A. Pulmonary Complications Secondary to Immune Checkpoint Inhibitors. Int J Chronic Dis. 2020; 2020:4928648 Epub 2020 Apr 23
    View PubMed
32. Duma N, Abdel-Ghani A, Yadav S, Hoversten KP, Reed CT, Sitek AN, Enninga EAL, Paludo J, Aguilera JV, Leventakos K, Lou Y, Kottschade LA, Dong H, Mansfield AS, Manochakian R, Adjei AA, Dronca RS. Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal? Oncologist. 2019 Nov; 24 (11):e1148-e1155 Epub 2019 Apr 29
    View PubMed
33. Murphy SJ, Harris FR, Kosari F, Barreto Siqueira Parrilha Terra S, Nasir A, Johnson SH, Serla V, Smadbeck JB, Halling GC, Karagouga G, Sukov WR, Leventakos K, Yang P, Peikert T, Mansfield AS, Wigle DA, Yi ES, Kipp BR, Vasmatzis G, Aubry MC. Using Genomics to Differentiate Multiple Primaries From Metastatic Lung Cancer. J Thorac Oncol. 2019 Sep; 14 (9):1567-1582 Epub 2019 May 16
    View PubMed
34. Leventakos K, Helgeson J, Mansfield AS, Deering E, Schwecke A, Adjei A, Molina J, Hocum C, Halfdanarson T, Marks R, Parikh K, Pomerleau K, Coverdill S, Rammage M, Haddad T. Implementation of artificial intelligence (AI) for lung cancer clinical trial matching in a tertiary cancer center. Ann Oncol. 2019 Apr; 30 Suppl 2:ii74
    View PubMed
35. Leventakos K, Schwecke AJ, Deering E, Cathcart-Rake E, Sanh AC, Jatoi A. The Need to Prioritize and Re-prioritize Palliative Care Options: Smoking Cessation as a Case-in-Point. Curr Treat Options Oncol. 2019 Mar 22; 20 (4):33
    View PubMed
36. Harris FR, Zhang P, Yang L, Hou X, Leventakos K, Weroha SJ, Vasmatzis G, Kovtun IV. Targeting HER2 in patient-derived xenograft ovarian cancer models sensitizes tumors to chemotherapy. Mol Oncol. 2019 Feb; 13 (2):132-152 Epub 2018 Dec 21
    View PubMed
37. Duma N, Azzouqa AG, Yadav S, Hoversten K, Reed C, Sitek AN, Lou Y, Molina J, Halfdanarson T, Leventakos K, Joseph RW, Manochakian R, Dronca R. Immune-related adverse events: Comparison of melanoma and non-small cell lung cancer patients treated with anti-PD1 therapy. Ann Oncol. 2018 Oct; 29 Suppl 8:viii432
    View PubMed
38. Duma N, Vera Aguilera J, Paludo J, Haddox CL, Gonzalez Velez M, Wang Y, Leventakos K, Hubbard JM, Mansfield AS, Go RS, Adjei AA. Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years. J Oncol Pract. 2018 Jan; 14 (1):e1-e10 Epub 2017 Nov 03
    View PubMed
39. Foukas PG, Tsiodras S, Economopoulou P, Spathis A, Mademli M, Leventakos K, Psyrri A, Karakitsos P, Panayiotides IG. Concomitant Human Herpes Virus 6 and nivolumab-related pneumonitis: Potential pathogenetic insights. IDCases. 2018; 11:101-103 Epub 2018 Feb 08
    View PubMed
40. Leventakos K, Peikert T, Midthun DE, Molina JR, Blackmon S, Nichols FC, Garces YI, Hallemeier CL, Murphy SJ, Vasmatzis G, Kratz SL, Holland WP, Thomas CF, Mullon JJ, Shen KR, Cassivi SD, Marks RS, Aubry MC, Adjei AA, Yang P, Allen MS, Edell ES, Wigle D, Mansfield AS. Management of Multifocal Lung Cancer: Results of a Survey. J Thorac Oncol. 2017 Sep; 12 (9):1398-1402 Epub 2017 June 03
    View PubMed
41. Leventakos K, Tsiodras S, Kelesidis T, Kefala M, Kottaridi C, Spathis A, Gouloumi AR, Pouliakis A, Pappas A, Sioulas V, Chrelias C, Karakitsos P, Panayiotides I. gammaH2Ax Expression as a Potential Biomarker Differentiating between Low and High Grade Cervical Squamous Intraepithelial Lesions (SIL) and High Risk HPV Related SIL. PLoS One. 2017; 12: (1)e0170626.
    View PubMed
42. Leventakos K, Kipp BR, Rumilla KM, Winters JL, Yi ES, Mansfield AS. S768I Mutation in EGFR in Patients with Lung Cancer. J Thorac Oncol. 2016 Oct; 11 (10):1798-801 Epub 2016 May 20
    View PubMed
43. Leventakos K, Mansfield AS. Advances in the Treatment of Non-small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab. BioDrugs. 2016 Oct; 30 (5):397-405
    View PubMed
44. Leventakos K, Mansfield AS, Blackmon S, Cassivi S, Shen R, Nichols FC, Molina JR, Allen MS, Aubry MC, Wigle D. 88P: Use of brain imaging in the management of patients with lymph node negative multifocal lung cancer. J Thorac Oncol. 2016 Apr; 11: (4 Suppl)S93-4.
    View PubMed
45. Tsiodras S, Poulakou G, Leventakos K, Panopoulou H, Elezoglou A, Manoloudaki K, Chrisofos M, Petrikkos G, Panayiotides IG. 'Prostate Abscess' as the Initial Manifestation of Granulomatosis with Polyangiitis (Wegener's Granulomatosis). Urol Int. 2016; 96 (2):244-6 Epub 2014 Aug 13
    View PubMed
46. Kouloulias V, Tolia M, Tsoukalas N, Papaloucas C, Pistevou-Gombaki K, Zygogianni A, Mystakidou K, Kouvaris J, Papaloucas M, Psyrri A, Kyrgias G, Gennimata V, Leventakos K, Panayiotides I, Liakouli Z, Kelekis N, Papaloucas A. Is there any potential clinical impact of serum phosphorus and magnesium in patients with lung cancer at first diagnosis? A multi-institutional study. Asian Pac J Cancer Prev. 2015; 16 (1):77-81
    View PubMed
47. Leventakos K, Mansfield AS. Reflections on immune checkpoint inhibition in non-small cell lung cancer. Transl Lung Cancer Res. 2014 Dec; 3 (6):411-3
    View PubMed
48. Lewis RE, Cahyame-Zuniga L, Leventakos K, Chamilos G, Ben-Ami R, Tamboli P, Tarrand J, Bodey GP, Luna M, Kontoyiannis DP. Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year autopsy study. Mycoses. 2013 Nov; 56 (6):638-45 Epub 2013 Apr 04
    View PubMed
49. Tsiodras S, Drogari-Apiranthitou M, Pilichos K, Leventakos K, Kelesidis T, Buitrago MJ, Petrikkos G, Panayiotides I. An unusual cutaneous tumor: African histoplasmosis following mudbaths: case report and review. Am J Trop Med Hyg. 2012 Feb; 86 (2):261-3
    View PubMed
50. Ben-Ami R, Garcia-Effron G, Lewis RE, Gamarra S, Leventakos K, Perlin DS, Kontoyiannis DP. Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance. J Infect Dis. 2011 Aug 15; 204 (4):626-35
    View PubMed
51. Lewis RE, Leventakos K, Liao G, Kontoyiannis DP. Efficacy of caspofungin in neutropenic and corticosteroid-immunosuppressed murine models of invasive pulmonary mucormycosis. Antimicrob Agents Chemother. 2011 Jul; 55 (7):3584-7 Epub 2011 May 02
    View PubMed
52. Evans SE, Leventakos K, Ben-Ami R, You D, Thakkar SG, Lewis RE, Kontoyiannis DP. Toll-deficient Drosophila are resistant to infection by Pneumocystis spp.: additional evidence of specificity to mammalian hosts. Virulence. 2010 Nov-Dec; 1 (6):523-5 Epub 2010 Nov 01
    View PubMed
53. Spathis A, Georgoulakis J, Foukas P, Kefala M, Leventakos K, Machairas A, Panayiotides I, Karakitsos P. KRAS and BRAF mutation analysis from liquid-based cytology brushings of colorectal carcinoma in comparison with formalin-fixed, paraffin-embedded tissue. Anticancer Res. 2010 Jun; 30 (6):1969-75
    View PubMed
54. Chamilos G, Bignell EM, Schrettl M, Lewis RE, Leventakos K, May GS, Haas H, Kontoyiannis DP. Exploring the concordance of Aspergillus fumigatus pathogenicity in mice and Toll-deficient flies. Med Mycol. 2010 May; 48 (3):506-10
    View PubMed
55. Ben-Ami R, Lewis RE, Leventakos K, Latge JP, Kontoyiannis DP. Cutaneous model of invasive aspergillosis. Antimicrob Agents Chemother. 2010 May; 54 (5):1848-54 Epub 2010 Feb 09
    View PubMed
56. Leventakos K, Lewis RE, Kontoyiannis DP. Fungal infections in leukemia patients: how do we prevent and treat them? Clin Infect Dis. 2010 Feb 1; 50 (3):405-15
    View PubMed
57. Ben-Ami R, Lewis RE, Tarrand J, Leventakos K, Kontoyiannis DP. Antifungal activity of colistin against mucorales species in vitro and in a murine model of Rhizopus oryzae pulmonary infection. Antimicrob Agents Chemother. 2010 Jan; 54 (1):484-90 Epub 2009 Oct 26
    View PubMed
58. Ben-Ami R, Lewis RE, Leventakos K, Kontoyiannis DP. Aspergillus fumigatus inhibits angiogenesis through the production of gliotoxin and other secondary metabolites. Blood. 2009 Dec 17; 114 (26):5393-9 Epub 2009 Oct 20
    View PubMed